CA2876306C - Deuterated derivatives of ruxolitinib - Google Patents

Deuterated derivatives of ruxolitinib Download PDF

Info

Publication number
CA2876306C
CA2876306C CA2876306A CA2876306A CA2876306C CA 2876306 C CA2876306 C CA 2876306C CA 2876306 A CA2876306 A CA 2876306A CA 2876306 A CA2876306 A CA 2876306A CA 2876306 C CA2876306 C CA 2876306C
Authority
CA
Canada
Prior art keywords
compound
salt
deuterium
hydrogen
myelofibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2876306A
Other languages
English (en)
French (fr)
Other versions
CA2876306A1 (en
Inventor
I. Robert Silverman
Julie F. Liu
Adam J. Morgan
Bhaumik PANDYA
Scott L. Harbeson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Sun Pharmaceutical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2876306(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries Inc filed Critical Sun Pharmaceutical Industries Inc
Publication of CA2876306A1 publication Critical patent/CA2876306A1/en
Application granted granted Critical
Publication of CA2876306C publication Critical patent/CA2876306C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2876306A 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib Active CA2876306C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US61/660,428 2012-06-15
US201261678795P 2012-08-02 2012-08-02
US61/678,795 2012-08-02
PCT/US2013/045919 WO2013188783A1 (en) 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib

Publications (2)

Publication Number Publication Date
CA2876306A1 CA2876306A1 (en) 2013-12-19
CA2876306C true CA2876306C (en) 2024-02-20

Family

ID=48699982

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2876306A Active CA2876306C (en) 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib

Country Status (19)

Country Link
US (7) US20150197525A1 (member.php)
EP (4) EP4606434A3 (member.php)
AU (3) AU2013274030B2 (member.php)
BR (1) BR122023027277A2 (member.php)
CA (1) CA2876306C (member.php)
DK (2) DK3450434T3 (member.php)
EA (1) EA201492287A1 (member.php)
ES (2) ES2867048T3 (member.php)
FI (1) FI3882249T3 (member.php)
HR (1) HRP20250965T1 (member.php)
IN (1) IN2014DN10670A (member.php)
LT (1) LT3882249T (member.php)
MX (2) MX373123B (member.php)
PL (2) PL3882249T3 (member.php)
PT (1) PT3882249T (member.php)
RS (1) RS67061B1 (member.php)
SI (1) SI3882249T1 (member.php)
SM (1) SMT202500302T1 (member.php)
WO (1) WO2013188783A1 (member.php)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184526B1 (en) 2005-12-13 2018-10-03 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor
TWI643857B (zh) 2010-03-10 2018-12-11 英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
MX344479B (es) 2011-06-20 2016-12-16 Incyte Holdings Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
PL3882249T3 (pl) 2012-06-15 2025-09-08 Sun Pharmaceutical Industries, Inc. Pochodne deuterowane ruksolitynibu
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN105579032A (zh) 2013-08-07 2016-05-11 因赛特公司 Jak1抑制剂的持续释放剂型
EP4233870A3 (en) 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
US10865203B2 (en) 2015-06-03 2020-12-15 Uwm Research Foundation, Inc. Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use
DK3411031T3 (da) 2016-02-04 2024-10-21 Cindome Pharma Inc Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser
CA3014275A1 (en) * 2016-02-12 2017-08-17 Vertex Pharmaceuticals (Europe) Limited Deuterium-modified cftr modulators
ES2988629T3 (es) 2016-05-04 2024-11-21 Sun Pharmaceutical Ind Inc Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados
EP3554485B9 (en) * 2016-12-14 2023-09-27 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
KR20240125702A (ko) 2017-06-30 2024-08-19 신돔 파마, 인크. 중수소화 돔페리돈 조성물, 방법, 및 제조
US20200281857A1 (en) 2017-11-22 2020-09-10 Dauntless 1, Inc. Therapeutic compound formulations
US20200353419A1 (en) 2017-11-22 2020-11-12 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
WO2019113487A1 (en) * 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3762424A1 (en) 2018-03-08 2021-01-13 Novartis AG Use of an anti-p-selectin antibody
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
JP7720697B2 (ja) 2018-03-30 2025-08-08 インサイト・コーポレイション Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
CN113906032A (zh) * 2019-02-06 2022-01-07 康塞特医药品有限公司 用于制备对映异构体富集的jak抑制剂的方法
AU2020232757B2 (en) 2019-03-05 2025-09-11 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
EP3941474A2 (en) 2019-03-19 2022-01-26 Incyte Corporation Biomarkers for vitiligo
WO2020210125A1 (en) 2019-04-10 2020-10-15 University Of Notre Dame Du Lac Deuterated antimicrobial compounds
WO2020223640A1 (en) 2019-05-02 2020-11-05 Intel Corporation Quality of service (qos) in information centric networking (icn)
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
WO2021053490A1 (en) 2019-09-16 2021-03-25 Novartis Ag Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
BR112022004225A2 (pt) 2019-09-16 2022-05-31 Novartis Ag Uso de um inibidor de mdm2 para o tratamento de mielofibrose
EP4041241A4 (en) 2019-09-27 2023-09-06 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSIS AND ASSOCIATED CONDITIONS
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP7518900B2 (ja) 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
CA3160312A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022036030A1 (en) 2020-08-12 2022-02-17 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
TW202227077A (zh) 2020-10-08 2022-07-16 瑞士商諾華公司 Ｅｒｋ抑制劑用於治療骨髓纖維化之用途
KR20230093504A (ko) 2020-10-28 2023-06-27 썬 파마슈티칼 인더스트리즈 인코포레이티드 중수소화된 jak 억제제를 이용한 탈모 장애의 치료를 위한 요법
WO2022107131A1 (en) * 2020-11-19 2022-05-27 Sol-Gel Technologies Ltd. Ruxolitinib or deuterated ruxolitinib composition and uses thereof
DK4255442T3 (da) 2020-12-04 2025-05-19 Incyte Corp Jak-hæmmer med d-vitamin-analog til behandling af hudsygdomme
JP2024503021A (ja) 2021-01-11 2024-01-24 インサイト・コーポレイション Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法
CN114853760B (zh) * 2021-02-03 2025-12-05 南京正大天晴制药有限公司 一种芦可替尼中间体的制备方法
EP4384175A1 (en) 2021-08-11 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US20240307401A1 (en) 2021-08-12 2024-09-19 Sun Pharmaceeutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN113820413B (zh) * 2021-09-17 2023-04-07 重庆华邦胜凯制药有限公司 高效液相色谱法分离测定磷酸芦可替尼及杂质的方法
IL316549A (en) 2022-05-04 2024-12-01 Sun Pharmaceutical Ind Inc Dosing regimens for treatment with dual JAK inhibitors
CN117384163A (zh) * 2022-07-05 2024-01-12 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途
WO2024196761A1 (en) * 2023-03-17 2024-09-26 Mayo Foundation For Medical Education And Research Use of oral jak kinase inhibitors to treat lichen planus
CN120917022A (zh) 2023-03-23 2025-11-07 葛兰素史密斯克莱知识产权(第3号)有限公司 氘代p2x3调节剂
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
US20250325664A1 (en) 2024-04-22 2025-10-23 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
DE60201988T2 (de) 2001-05-03 2005-12-15 F. Hoffmann-La Roche Ag Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
KR20070083839A (ko) 2004-09-29 2007-08-24 코디스 코포레이션 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태
WO2007041630A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP3184526B1 (en) * 2005-12-13 2018-10-03 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
MX342814B (es) * 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2242493B1 (en) 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
PL3882249T3 (pl) 2012-06-15 2025-09-08 Sun Pharmaceutical Industries, Inc. Pochodne deuterowane ruksolitynibu
NZ708157A (en) * 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib

Also Published As

Publication number Publication date
PL3882249T3 (pl) 2025-09-08
IN2014DN10670A (member.php) 2015-08-28
SI3882249T1 (sl) 2025-10-30
BR112014031204A2 (pt) 2017-06-27
US20150197525A1 (en) 2015-07-16
US20230355629A1 (en) 2023-11-09
EP4606434A3 (en) 2025-12-03
EP2861600A1 (en) 2015-04-22
US9249149B2 (en) 2016-02-02
LT3882249T (lt) 2025-08-25
DK3450434T3 (da) 2021-05-03
AU2013274030B2 (en) 2016-07-07
PL3450434T3 (pl) 2021-10-04
MX2014015185A (es) 2015-02-17
US20250025467A1 (en) 2025-01-23
AU2016238877A1 (en) 2016-10-27
BR122023027277A2 (pt) 2024-01-23
AU2018271227A1 (en) 2018-12-13
EP3882249B1 (en) 2025-05-14
WO2013188783A8 (en) 2014-02-27
EA201492287A1 (ru) 2015-07-30
AU2016238877B2 (en) 2018-08-30
HRP20250965T1 (hr) 2025-10-10
CA2876306A1 (en) 2013-12-19
ES3037872T3 (en) 2025-10-07
EP3450434A1 (en) 2019-03-06
US20210330674A1 (en) 2021-10-28
SMT202500302T1 (it) 2025-09-12
US20190308976A1 (en) 2019-10-10
EP3882249A1 (en) 2021-09-22
AU2018271227B2 (en) 2020-08-27
AU2013274030A1 (en) 2015-01-22
MX373123B (es) 2020-04-27
FI3882249T3 (fi) 2025-08-11
EP4606434A2 (en) 2025-08-27
WO2013188783A1 (en) 2013-12-19
US20170239254A1 (en) 2017-08-24
US20150239896A1 (en) 2015-08-27
RS67061B1 (sr) 2025-08-29
MX360495B (es) 2018-11-06
PT3882249T (pt) 2025-08-06
ES2867048T3 (es) 2021-10-20
DK3882249T3 (da) 2025-08-25
EP3450434B1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
CA2876306C (en) Deuterated derivatives of ruxolitinib
AU2013296627B2 (en) Deuterated ibrutinib
JP6367545B2 (ja) ルキソリチニブの重水素化誘導体
CA2904054A1 (en) Deuterated palbociclib
CN104725380B (zh) 卢索替尼的氘代衍生物
US20140128469A1 (en) Deuterated n-butyl bumetanide
KR102433283B1 (ko) 룩소리티닙의 중수소화된 유도체
HK40060909A (en) Deuterated derivatives of ruxolitinib
HK40060909B (en) Deuterated derivatives of ruxolitinib
JP6830460B2 (ja) ルキソリチニブの重水素化誘導体
HK40013863B (en) Deuterated derivatives of ruxolitinib
HK40013863A (en) Deuterated derivatives of ruxolitinib
EP2678337A1 (en) 2-amino-naphthyridine derivatives
BR112014031204B1 (pt) Derivados deuterados de ruxolitinib e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614

EEER Examination request

Effective date: 20180614